Inpharma

Surpassing the success of imatinib mesylate in CML
pp. 2-2(1)

Paediatric vitamin D intake guidelines released
pp. 3-3(1)

Why drugs fail in clinical practice
pp. 3-3(1)

The first microarray based on the SARS coronavirus genome has been developed
pp. 3-3(1)

Angiotensin II receptor antagonists may decrease mortality in patients with SARS
pp. 3-3(1)

The development of a clinical grade vaccine against SARS will begin
pp. 3-3(1)

The International Society of Hypertension (ISH) has released a guideline statement on the lowering of BP and the prevention of stroke
pp. 4-4(1)

Biotechnology industry on economic roller-coaster
pp. 4-4(1)

Phage therapy: new weapon against infectious diseases?
pp. 4-4(1)

Pfizer and Pharmacia have combined operations to create the world's largest research-based pharmaceutical company.
pp. 4-4(1)

Only one in five UK anaesthetists routinely give IV magnesium sulfate during heart surgery
pp. 5-5(1)

Which hepatitis C therapy worth it in IFN- nonresponders?
pp. 5-5(1)

Antineoplastic therapy is frequently used in the last 3 months of life among US Medicare beneficiaries with cancer
pp. 5-5(1)

Rofecoxib superior to celecoxib, paracetamol, following ENT surgery
pp. 5-5(1)

Meloxicam cost saving over piroxicam and diclofenac in OA
pp. 6-6(1)

Weekly tafenoquine prevents P. falciparum malaria
pp. 6-6(1)

Lymecycline good value for money in acne vulgaris
pp. 6-6(1)

Efalizumab: durable benefits in plaque psoriasis
pp. 7-9(3)

Alteplase plus captopril induces antiangiogenic activity in plasma
pp. 9-9(1)

The initial response to enfuvirtide is maintained at 48 weeks among patients with HIV-1 infections
pp. 9-9(1)

Ivabradine shows potential in angina pectoris
pp. 10-10(1)

Oral zebularine reactivates silenced genes
pp. 10-10(1)

Omega-3 fatty acid monotherapy was successful in the treatment of major depressive disorder in a 34-year-old pregnant woman
pp. 11-11(1)

HIV vaccine vCP205: results from trial based in Uganda
pp. 11-11(1)

Pregabalin effective in generalised anxiety disorder
pp. 11-11(1)

-Blockers in heart failure: who gains the most?
pp. 12-12(1)

"Pregabalin dosage adjustment should be considered for patients with CLcr values of < 60 mL/min"
pp. 12-12(1)

Efaproxiral [RSR13] is associated with a positive survival benefit in patients with brain metastases
pp. 12-12(1)

Montelukast effective in managing allergic rhinitis
pp. 13-14(2)

Terbinafine plus voriconazole helped to control disseminated Scedosporium prolificans infection in a 53-year-old woman
pp. 14-14(1)

Delayed immunisation increases the risk of hospital admission in infants with pertussis
pp. 14-14(1)

Antioxidants slow atherosclerotic progression
pp. 15-15(1)

Pamidronic acid appears to be beneficial in paediatric patients with osteogenesis imperfecta
pp. 15-15(1)

Acetylcholine receptor antagonists for overactive bladder: significance?
pp. 15-15(1)

Sublingual misoprostol is effective for cervical ripening prior to vacuum aspiration
pp. 15-15(1)

Verapamil for preventing adverse cardiovascular events
pp. 16-16(1)

IV pulse cyclophosphamide in refractory IBD
pp. 16-16(1)

Intravaginal clindamycin reduces preterm labour
pp. 16-16(1)

Tetrathiomolybdate treats neurological effects of Wilson's disease
pp. 17-17(1)

Montelukast brings relief in seasonal allergic rhinitis
pp. 17-17(1)

Montelukast + budesonide improves asthma control
pp. 17-17(1)

GPIIb-IIIa antagonists in ACS and renal impairment
pp. 19-19(1)

Magnesium improves outcomes in coronary artery disease
pp. 19-19(1)

News from the 61st Annual Meeting of the American Academy of Dermatology
pp. 20-22(3)

Atorvastatin reduces proteinuria in chronic kidney disease
pp. 22-22(1)

Rosuvastatin improves lipid parameters in patients with hypercholesterolaemia and metabolic syndrome
pp. 22-22(1)

Paclitaxel-eluting stents reduce restenosis
pp. 23-23(1)

3-Hydroxybutyric acid improves cerebral and cardiac complications in severe fatty acid oxidation defects
pp. 23-23(1)

Metallothionein overexpression predicts bladder tumour resistance to intravesical mitomycin therapy
pp. 23-23(1)

Tamoxifen cuts incidence of benign breast disease in at-risk women
pp. 23-23(1)

Benziodarone vs allopurinol for post-transplant hyperuricaemia
pp. 24-24(1)

Prednisone successfully treated recurrent intussusception associated with intestinal lymphoid hyperplasia (ILH) in two paediatric patients
pp. 24-24(1)

Magnesium supplementation improves insulin sensitivity
pp. 24-24(1)

"A personalized rhTSH [thyrotropin alfa] dose, adjusted for BSA, should be used in clinical practice"
pp. 25-25(1)

Diltiazem may prevent renal damage after cardiac surgery
pp. 25-25(1)

Risperidone normalises elevated superoxide dismutase levels in patients with schizophrenia
pp. 25-25(1)

Some benefit with rofecoxib in chronic nonbacterial prostatitis
pp. 25-25(1)

Long-term statin therapy: no negative effects on IMT
pp. 26-26(1)

Clopidogrel reduces platelet-leucocyte aggregate formation
pp. 26-26(1)

Amitriptyline dampens the hypothalamus-pituitary-adrenal (HPA) system to a greater extent than paroxetine
pp. 26-26(1)

Dexamethasone beneficial in neonatal RDS
pp. 27-27(1)

Cutaneous CYP2S1: role in metabolism of psoriasis drugs?
pp. 27-27(1)

Inhaled heparin reduces airway hyperreactivity in allergic asthma
pp. 27-27(1)

EMEA highlights important `Ketek' safety information
pp. 28-28(1)

Nurses make valuable contribution to ADR reporting
pp. 28-28(1)

Prenatal exposure to diuretics and hypertension linked to schizophrenia
pp. 28-28(1)

Treatment with mercaptopurine is associated with a higher incidence of fetal loss
pp. 28-28(1)

Adverse drug events in outpatients
pp. 29-29(1)

EU market news
pp. 29-29(1)

The disease-modifying antirheumatic drug leflunomide [`Arava'; Aventis] has been granted importing approval in Japan
pp. 29-29(1)

Tocopherol [vitamin E] supplementation decreases the risk and severity of cisplatin-induced peripheral neuropathy
pp. 29-29(1)

The UK Department of Health has announced the first phase of patient reporting of suspected adverse drug reactions
pp. 29-29(1)

US market news
pp. 30-30(1)

Aztreonam [`Treonam'; Citadel Aurobindo Biotech Limited] has been launched in India
pp. 30-30(1)

Lumiracoxib [`Prexige'; Novartis] has been approved in Mexico
pp. 30-30(1)

Product Introductions
pp. 31-31(1)